Lixte Stock Analysis

LIXT -  USA Stock  

USD 2.92  0.05  1.68%

The newest Lixte Biotech Hlds price drop may encourage private investors to take a closer look at the firm as it is trading at a share price of 2.92 on 15,700 in trading volume. The company executives were unable to exploit market volatilities in May. However, diversifying your overall positions with Lixte Biotech can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.17. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Lixte Biotech Hlds partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Lixte Biotech stock analysis report makes it easy to digest most publicly released information about Lixte Biotech and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Lixte stock analysis module also helps to analyze the Lixte Biotech price relationship with some important fundamental indicators such as market cap and management efficiency.

Lixte Stock Analysis Notes

About 68.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.29. Lixte Biotech Hlds had not issued any dividends in recent years. The entity had 1-6 split on the 20th of November 2020. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Lixte Biotech Hlds contact John Kovach at 631-830-7092 or learn more at http://www.lixte.com.

Lixte Biotech Hlds Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Lixte Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Lixte Biotech Hlds or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Lixte Biotech Hlds generates negative expected return over the last 90 days
Lixte Biotech Hlds has high historical volatility and very poor performance
Lixte Biotech Hlds has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 200 K. Net Loss for the year was (4.61 M) with profit before overhead, payroll, taxes, and interest of 0.
Lixte Biotech Hlds currently holds about 7.74 M in cash with (2.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57.
Roughly 68.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.equities.com: Lixte Biotech Hlds falls 6.32 percent for May 24 - Equities.com

Lixte Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Lixte Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lixte Biotech Hlds backward and forwards among themselves. Lixte Biotech's institutional investor refers to the entity that pools money to purchase Lixte Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Almanack Investment Partners LlcCommon SharesM3.4 M
Santa Monica Partners LpCommon Shares166.7 K548 K
Sabby Management LlcCommon Shares79.7 K262 K
Sabby Management LlcWarrants157.4 K128 K
Citadel Advisors LlcCommon Shares23.8 K79 K
Morgan StanleyCommon Shares21.1 K69 K
Tower Research Capital Llc TrcCommon Shares1.6 KK
Blackrock IncCommon Shares3031000
Note, although Lixte Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lixte Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 40.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lixte Biotech's market, we take the total number of its shares issued and multiply it by Lixte Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (56.61) % which means that it has lost $56.61 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (95.04) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotech management efficiency ratios could be used to measure how well lixte biotech hlds manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 19th of June, Lixte Biotech secures the mean deviation of 3.66, and Risk Adjusted Performance of (0.028396). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lixte Biotech Hlds, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Lixte Biotech, which can be compared to its peers in the industry. Please verify Lixte Biotech Hlds standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Lixte Biotech Hlds is priced some-what accurately, providing market reflects its recent price of 2.92 per share. Please also check out Lixte Biotech total risk alpha, which is currently at (0.61) to check the company can sustain itself at a future point.

Lixte Biotech Hlds Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Lixte Biotech Hlds Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lixte Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lixte Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lixte Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Lixte Biotech Predictive Daily Indicators

Lixte Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lixte Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Lixte Biotech Forecast Models

Lixte Biotech time-series forecasting models is one of many Lixte Biotech's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lixte Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Lixte Biotech Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lixte Biotech stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lixte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Lixte Biotech. By using and applying Lixte Stock analysis, traders can create a robust methodology for identifying Lixte entry and exit points for their positions.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Lixte Biotech to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module
Additionally, see Stocks Correlation. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Lixte Biotech Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.